Testing Several Treatments to Slow Chronic Kidney Disease in Adults
Tests finerenone and semaglutide in adults with chronic kidney disease.
Plain-language title generated from the registry record
Registry title: The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
Key facts
- Where
- Auckland, Dunedin, Hastings, Palmerston North, and Whangarei, New ZealandSee the 7 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic kidney disease from any cause who still have some kidney function and are on standard care. It tests extra treatments to slow the disease.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Chronic kidney disease from any cause, with eGFR of 25 mL/min/1.73m2 or higher. For the finerenone and semaglutide parts, a urine albumin-creatinine ratio above 200 mg/g or a urine protein-creatinine ratio above 300 mg/g is also asked for.
- Earlier treatment
- Must be getting standard care for kidney disease. For the finerenone and semaglutide parts, this must be stable for 4 weeks before screening, including an SGLT2i unless there is a documented reason not to use one.
- Biomarker or test result
- eGFR 25 or higher. Urine albumin-creatinine ratio above 200 mg/g or urine protein-creatinine ratio above 300 mg/g for both treatment parts. Finerenone part: potassium below 5.0 mmol/L. Semaglutide part: HbA1c 10% (86 mmol/mol) or lower and BMI from 23 to under 50 kg/m2.
Main reasons for not taking part
- Planned to start kidney replacement therapy or have a kidney transplant in the next 6 months
- Life expectancy of less than 6 months
- Kidney transplant recipient (for the finerenone and semaglutide parts)
- Currently pregnant or breastfeeding, or planning to become pregnant (for both treatment parts)
- Allergy, intolerance or contraindication to finerenone (MRAs) or semaglutide (GLP-1 RAs), depending on the part
Read by machine on 9 November 2026.
Where in New Zealand
- Aotearoa Clinical Trials Trust, Middlemore HospitalAuckland, New ZealandTaking people
- Auckland City HospitalAuckland, New ZealandTaking people
- Health New Zealand, Te Whatu Ora Waitemata, North Shore HospitalAuckland, New ZealandTaking people
- 201 Great King Street, Central Dunedin, Dunedin 9016, New ZealandDunedin, New ZealandTaking people
- Health New Zealand, Te Whatu Ora Te Matau a Maui, Hawke's Bay HospitalHastings, New ZealandTaking people
- Midcentral - Palmerston North HospitalPalmerston North, New ZealandTaking people
- Private Bag 9742 Maunu Road, Horahora, Whangārei 0148, New ZealandWhangarei, New ZealandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- The George Institute
- Trial code
- NCT06058585EU 2024-520253-21-00
- Record updated
- 5 October 2026
- Original description
CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD).Read full original descriptionShow less
The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD).
CAPTIVATE aims to find the best treatment, or combination of treatments, that slow the progression of CKD so that fewer people develop kidney failure.
CAPTIVATE provides a research platform that allows many treatment-related questions to be answered within a common trial set-up.
CAPTIVATE includes multiple domains examining different therapies for CKD. Participants may enrol in one or more domains and domains will be added and closed over time. The platform operates under a core protocol with each domain described in a domain specific appendix.
Inclusion: Age ≥ 18 years; Known chronic kidney disease from any cause (eGFR ≥25 mL/min/1.73m2); Currently receiving standard of care treatment according to treating physician; Eligible for randomisation in at least one recruiting domain-specific appendix; Participant and treating physician are willing and able to perform trial procedures; Urine albumin-creatinine ratio (uACR) >200 mg/g (22.6 mg/mmol) or urine protein-creatinine ratio (uPCR) >300 mg/g (33.9 mg/mmol) at time of screening; On a stable standard of care treatment for CKD, including a SGLT2i unless there is a documented reason not to be using a SGLT2i*, for 4 weeks before screening according to treating physician; Treating physician believes finerenone is clinically appropriate for the participant; Participant and treating physician are willing and able to perform MRA DSA procedures; Provision of written informed consent or eConsent following a fully informed discussion and prior to performing any MRA DSA related procedures; Urine albumin-creatinine ratio (uACR) >200 mg/g (22.6 mg/mmol) or urine proteincreatinine ratio (uPCR) >300 mg/g (33.9 mg/mmol) at time of screening; On a stable standard of care treatment for CKD, including a SGLT2i and maximum tolerated ACEi/ARB unless there is a documented reason not to be using a SGLT2i, for 4 weeks before screening; HbA1c less than or equal to 10% (less than or equal to 86mmol/L); BMI ≥23 kg/m2 and < 50 kg/m2; Treating physician believes semaglutide is clinically appropriate for the participant; Participant and treating physician are willing and able to perform GLP-1 RA DSA procedures; Provision of written informed consent or eConsent following a fully informed discussion and prior to performing any GLP-1 RA DSA related procedures.
Exclusion: Planned to commence kidney replacement therapy or kidney transplant surgery in next 6 months; Recipient of kidney transplant; Current treatment with MRA, where the treating physician or patient is not willing to discontinue this medication. If willing to discontinue the MRA, the potential participant must be re-screened after they have been on stable standard of care treatment for 4 weeks without the MRA; Current treatment with strong CYP3A4 inhibitors; Systolic BP <110 mmHg or diastolic BP<55 mmHg without antihypertensive therapy at time of screening; Recipient of kidney transplant; Major adverse cardiovascular events (MACE), consisting of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death, within 90 days prior to the day of screening; Previous episode of pancreatitis; Current treatment with a GLP-1 RA, where it is in the participant's best interests to continue the GLP-1 RA or where the treating physician or patient is not willing to discontinue this medication for a minimum of 4 weeks prior to randomisation and for the full duration of the trial (ie. 108 weeks if assigned to placebo); Known allergy, intolerance or contraindication to MRAs; Severe hepatic impairment (defined as Child-Pugh Class C); Adrenal insufficiency; Presently classified as being in New York Heart Association (NYHA) Class IV heart failure; Personal or first-degree relative(s) with a history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma (MTC); Uncontrolled thyroid disease TSH>6.0 mIU/L or <0.4mlU/L; Type 1 diabetes; Known allergy, intolerance, or contraindication to GLP-1 RAs; Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol; Hyperkalaemia (serum potassium ≥5.0 mmol/L) at time of screening; Life expectancy less than 6 months; To be included in any of the following DOMAINS the participant must met eligible for the PLATFORM (as listed above); MRA domain; Currently pregnant or breast feeding, or intending to become pregnant; GLP-1 RA Domain; Currently pregnant or breast feeding, or intending to become pregnant or is of child-bearing potential, and not using a highly effective contraceptive method.